Beyond ADCs: Payload-Free Tumor Killing Through MUC16-Guided DR5 Superclustering
- Why ADCs hit a ceiling: Payload-driven toxicity narrows therapeutic windows and confines benefit to high-antigen-expressing tumors. Even leading approved programs struggle to reach the moderate- and low-expressing patients who often make up most of the addressable population
- The Cancerlysin™ Solution: Antigen-guided DR5 superclustering. MUC16 binding by IMV-M™ triggers tumor-localized DR5 superclustering and extrinsic apoptotic signaling with no cytotoxic payload. Single-agent regressions in pancreatic, lung, and ovarian xenograft models; clean NHP safety to 4× therapeutic dose with zero hepatotoxicity; projected patient eligibility of 50% in NSCLC and 64–92% in ovarian – multiples over leading DXd-ADCs in the same indications
- A platform built for what comes after ADCs. The Cancerlysin™ platform extends to IMV-C (colorectal, gastric) and IMV-5 (AML); its payload-free architecture is compatible with standard antibody manufacturing – no linker chemistry, no DAR control, no payload-related regulatory burden